PuriCore Raises $9.74 Million

MALVERN, PENNSYLVANIA, AND STAFFORD, UK, 1 October 2008 — PuriCore plc (LSE: PURI), the life sciences company focused on developing and commercialising proprietary, green solutions that safely, effectively, and naturally kill infectious pathogens, today announces that it has closed on a new $9.74 million debt facility with Commerce Commercial Leasing. The debt is structured as a 36-month promissory note with an imputed interest rate of 7.7%. This financing is consistent with the company’s strategy as communicated in the Interim Results to monetize cash flows from existing Food Retail lease contracts. Of the $9.74 million, approximately $1.1 million will be used to extinguish existing higher cost debt, with the balance for general working capital.

Enquiries: Ben Brewerton Susan Quigley Financial Dynamics +44 (0) 20 7831 3113

About PuriCore

PuriCore plc (LSE: PURI) is a life sciences company focused on developing and commercialising proprietary green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment. PuriCore targets markets that depend upon controlling contamination, including food safety in retail and foodservice, medical device disinfection, and wound therapy. The Company’s patented, proprietary technology mimics the human body’s production of the natural antimicrobial hypochlorous acid, which is highly effective in killing bacteria, viruses, and fungal spores, simply from water, common salt, and electricity. Hypochlorous acid is proven to be safe, environmentally friendly, and fast acting against a broad range of infectious pathogens, including major public health threats of M. tuberculosis, MRSA, E.coli, Norovirus, H5N1 Avian Influenza, HIV, Salmonella, Polio Virus, Helicobater pylori, and Legionella. PuriCore is headquartered in Malvern, Pennsylvania, with offices in Stafford, UK.